References
1. Fried I, Tabori U, Tihan T, Reginald A, Bouffet E. Optic pathway
gliomas: a review. CNS Oncol . Mar 2013;2(2):143-59.
doi:10.2217/cns.12.47
2. Czyzyk E, Jozwiak S, Roszkowski M, Schwartz RA. Optic pathway gliomas
in children with and without neurofibromatosis 1. J Child Neurol .
Jul 2003;18(7):471-8. doi:10.1177/08830738030180070401
3. Fangusaro J, Witt O, Hernáiz Driever P, et al. Response assessment in
paediatric low-grade glioma: recommendations from the Response
Assessment in Pediatric Neuro-Oncology (RAPNO) working group. The
Lancet Oncology . 2020;21(6):e305-e316.
doi:10.1016/S1470-2045(20)30064-4
4. Heidary G, Fisher MJ, Liu GT, et al. Visual field outcomes in
children treated for neurofibromatosis type 1-associated optic pathway
gliomas: a multicenter retrospective study. Journal of AAPOS : the
official publication of the American Association for Pediatric
Ophthalmology and Strabismus . 2020;24(6):349.e1-349.e5.
doi:10.1016/j.jaapos.2020.07.013
5. Zhukova N, Rajagopal R, Lam A, et al. Use of bevacizumab as a single
agent or in adjunct with traditional chemotherapy regimens in children
with unresectable or progressive low-grade glioma. Cancer
medicine . 2019;8(1):40-50. doi:10.1002/cam4.1799
6. Avery RA, Hwang EI, Jakacki RI, Packer RJ. Marked recovery of vision
in children with optic pathway gliomas treated with bevacizumab.JAMA ophthalmology . 2014;132(1):111-4.
doi:10.1001/jamaophthalmol.2013.5819
7. Hwang EI, Jakacki RI, Fisher MJ, et al. Long-term efficacy and
toxicity of bevacizumab-based therapy in children with recurrent
low-grade gliomas. Pediatric blood & cancer . 2013;60(5):776-82.
doi:10.1002/pbc.24297
8. Green K, Panagopoulou P, D’Arco F, et al. A Nationwide Evaluation of
Bevacizumab-based Treatments in Paediatric Low-Grade Glioma in the UK:
Safety. Efficacy, Visual Morbidity and Outcomes. Neuro Oncol . Oct
14 2022;doi:10.1093/neuonc/noac223
9. Yamasaki F, Takano M, Yonezawa U, et al. Bevacizumab for optic
pathway glioma with worsening visual field in absence of imaging
progression: 2 case reports and literature review. Child’s Nervous
System . 2020;36(3):635-639. doi:10.1007/s00381-019-04407-6
10. Hill CS, Devesa SC, Ince W, Borg A, Aquilina K. A systematic review
of ongoing clinical trials in optic pathway gliomas. Child’s
nervous system : ChNS : official journal of the International Society
for Pediatric Neurosurgery . 2020;doi:10.1007/s00381-020-04724-1
11. Fisher MJ, Avery RA, Allen JC, et al. Functional outcome measures
for NF1-associated optic pathway glioma clinical trials.Neurology . 2013;81(21 Suppl 1):S15-24.
doi:10.1212/01.wnl.0000435745.95155.b8
12. Falzon K, Drimtzias E, Picton S, Simmons I. Visual outcomes after
chemotherapy for optic pathway glioma in children with and without
neurofibromatosis type 1: Results of the international society of
paediatric oncology (siop) low-grade glioma 2004 trial UK cohort.British Journal of Ophthalmology . 2018;102(10):1367-1371.
doi:10.1136/bjophthalmol-2017-311305
13. Thirunavu VM, Mohammad LM, Kandula V, Beestrum M, Lam SK. Vision
Outcomes for Pediatric Patients With Optic Pathway Gliomas Associated
With Neurofibromatosis Type I: A Systematic Review of the Clinical
Evidence. Journal of pediatric hematology/oncology .
2021;00(00):1-9. doi:10.1097/MPH.0000000000002060
14. Wan MJ, Ullrich NJ, Manley PE, Kieran MW, Goumnerova LC, Heidary G.
Long-term visual outcomes of optic pathway gliomas in pediatric patients
without neurofibromatosis type 1. Journal of neuro-oncology .
2016;129(1):173-8. doi:10.1007/s11060-016-2163-4